IHC assays used to detect the presence of PD-L1 protein in tumor tissues are designed and needed to aid clinical treatment decisions by identifying cancer patients most likely to respond to antibody therapies that target the PD-1/PD-L1 pathway. The gene discussed is PDCD1; the disease is cancer.